IsoRay Inc
XBER:AAJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mahamaya Steel Industries Ltd
NSE:MAHASTEEL
|
IN |
IsoRay Inc
EPS (Diluted)
IsoRay Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
IsoRay Inc
XBER:AAJ
|
EPS (Diluted)
$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$6
|
CAGR 3-Years
23%
|
CAGR 5-Years
132%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$14
|
CAGR 3-Years
6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
5%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$15
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$41
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
22%
|
|
IsoRay Inc
Glance View
IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The company is headquartered in Richland, Washington and currently employs 61 full-time employees. The company went IPO on 2002-05-31. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The firm is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The firm's Cesium-131 seed is classified as a Class II device.
See Also
What is IsoRay Inc's EPS (Diluted)?
EPS (Diluted)
-0.2
USD
Based on the financial report for Mar 31, 2024, IsoRay Inc's EPS (Diluted) amounts to -0.2 USD.
What is IsoRay Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
0%
Over the last year, the EPS (Diluted) growth was -167%. The average annual EPS (Diluted) growth rates for IsoRay Inc have been -100% over the past three years , -10% over the past five years .
